Last updated: July 27, 2026
Vanda Pharmaceuticals v. Apotex (0:22-cv-62432): Litigation Summary, Patent Issues, and Generic Risk Analysis
Vanda Pharmaceuticals Inc. v. Apotex Inc., case no. 0:22-cv-62432, is an IP infringement dispute tied to Vanda’s U.S. pharmaceutical patent estate in which Apotex is positioned as a potential generic entrant. The record required to produce a complete litigation summary and enforceable infringement/patent-expiration analysis is not available in the provided materials, so no data-driven case-specific conclusions can be issued.
What patents are asserted in Vanda Pharmaceuticals v. Apotex 0:22-cv-62432?
A litigation summary that is usable for licensing, litigation budgeting, and launch-risk modeling requires the asserted patent numbers, statutory claims (35 USC §§ 271(a), (e)(2), or induced/direct infringement), and the specific claims of each patent that Vanda alleges are infringed. Those items are not present in the available input.
Which patent families are likely at issue (and what claims typically drive these cases)?
For Orange Book-driven Vanda disputes, common asserted categories include:
- Composition-of-matter
- Method-of-use (clinical dosing/indication claims)
- Formulation or formulation/process claims
- Drug-device or administration-related claims (if applicable to the product)
No product identity, Orange Book listing, or asserted-claim chart is provided for this docket, so no mapping from generic filing theories to patent families can be stated.
What is the procedural posture of 0:22-cv-62432 (motions, scheduling order, and trial status)?
A meaningful posture analysis requires:
- Complaint filing date and any amended pleadings
- Responsive pleadings (answer, counterclaims)
- Claim construction activity (Markman)
- Discovery status
- Summary judgment rulings
- Final judgment or settlement docket entries
The provided information includes only the caption-level case identifier and not the docket events. Without those entries, any statement about motion outcomes or timing would be non-factual.
Has Vanda asserted Paragraph IV or 505(b)(2) or ANDA-specific theories in 0:22-cv-62432?
To determine whether the case is an ANDA Paragraph IV framework, and to analyze generic entry exposure, the record must include:
- The FDA application type referenced in the pleadings
- The Orange Book listed patents at issue
- The statutory hook (typically 35 USC § 271(e)(2) for ANDA Paragraph IV)
Those details are not supplied. Without them, the correct exclusivity and generic-launch-risk model cannot be produced.
When does Vanda’s exclusivity and the asserted patents expire for this case?
A launch-risk analysis depends on:
- The expiration dates of the specific asserted patents
- Any regulatory exclusivities (NCE, data, pediatric exclusivity)
- PTA (patent term adjustment) and PTE (patent term extension) effects, when applicable
- Any terminal disclaimers
No asserted patent list or FDA exclusivity records for the specific product are provided, so the expiration timeline cannot be calculated or stated.
How strong is Vanda’s patent estate for the underlying product in this docket?
Patent-strength scoring requires at least one of:
- Asserted patent claim numbers and independent/dependent structure
- Claim construction rulings
- Prior validity challenges or PTO reexamination/IPR outcomes
- Evidence described in the complaint (product differences, infringement mechanisms)
The required docket-specific details are missing, so no strength assessment can be made.
What generic entry risks exist for Apotex if Vanda loses in 0:22-cv-62432?
Launch exposure analysis depends on:
- Whether the patents-in-suit are dispositioned (invalidated, non-infringed, or not infringed)
- Whether a settlement triggers “entry-for-claim” dates
- Whether injunction scope is limited to specific claims or products
- Whether there is a later appeal
No disposition facts are included.
What settlement terms or stipulations govern Apotex versus Apotex in 0:22-cv-62432?
Settlement analysis requires:
- Dates of settlement, if any
- Entry-for-launch provisions
- Payment terms (if available)
- Agreement on remaining patents or dismissal with/without prejudice
No settlement entries are provided.
What is the FDA status and Orange Book listing relevance for this Vanda vs. Apotex litigation?
Orange Book status is needed to connect:
- Application number and applicant (Apotex)
- Listed patents and their expiration/30-month stay behavior
- Whether exclusivities block entry even if an injunction lifts
No FDA application identifiers or Orange Book listing details are provided for this docket.
Key Takeaways
- Vanda Pharmaceuticals Inc. v. Apotex Inc., case no. 0:22-cv-62432, is identified at the docket level, but the information required to summarize asserted patents, procedural posture, infringement/validity issues, exclusivity timelines, and case outcomes is not provided.
- No patent-expiration or generic-entry conclusions can be issued without the asserted-patent list and docket event history.
FAQs
- What patents are typically asserted in Vanda generic litigation involving Apotex?
- Does docket 0:22-cv-62432 involve an ANDA Paragraph IV notice?
- How do PTA and pediatric exclusivity affect Vanda patent expiry timelines?
- What procedural milestones (Markman, summary judgment) commonly decide these cases?
- If Apotex is enjoined, what are the usual pathways to launch after appeal or settlement?
References
- Vanda Pharmaceuticals Inc. v. Apotex Inc., case no. 0:22-cv-62432.
